Proficio Capital Partners LLC Invests $155,000 in SI-BONE, Inc. (NASDAQ:SIBN)

Proficio Capital Partners LLC purchased a new position in SI-BONE, Inc. (NASDAQ:SIBN) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 11,048 shares of the company’s stock, valued at approximately $155,000.

Several other large investors have also recently modified their holdings of the stock. FMR LLC raised its position in SI-BONE by 103.6% in the 3rd quarter. FMR LLC now owns 2,354 shares of the company’s stock worth $33,000 after buying an additional 1,198 shares during the last quarter. Mainstream Capital Management LLC bought a new stake in SI-BONE during the fourth quarter valued at approximately $53,000. R Squared Ltd purchased a new position in SI-BONE during the fourth quarter valued at $73,000. Walleye Capital LLC purchased a new stake in shares of SI-BONE in the third quarter worth $144,000. Finally, Versor Investments LP bought a new stake in SI-BONE during the fourth quarter valued at about $185,000. Hedge funds and other institutional investors own 98.11% of the company’s stock.

SI-BONE Trading Up 0.4 %

NASDAQ SIBN opened at $14.04 on Friday. The stock has a market cap of $596.04 million, a PE ratio of -15.26 and a beta of 1.17. The company has a current ratio of 8.25, a quick ratio of 7.22 and a debt-to-equity ratio of 0.22. SI-BONE, Inc. has a 12 month low of $11.70 and a 12 month high of $19.16. The company’s 50-day moving average price is $16.41 and its 200-day moving average price is $14.78.

SI-BONE (NASDAQ:SIBN) last announced its quarterly earnings results on Monday, February 24th. The company reported ($0.11) EPS for the quarter, beating the consensus estimate of ($0.16) by $0.05. The firm had revenue of $49.00 million for the quarter, compared to analyst estimates of $48.87 million. SI-BONE had a negative return on equity of 22.51% and a negative net margin of 23.82%. Equities research analysts forecast that SI-BONE, Inc. will post -0.78 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts recently weighed in on SIBN shares. Truist Financial restated a “buy” rating and set a $22.00 target price (up previously from $18.00) on shares of SI-BONE in a research report on Tuesday, February 25th. Needham & Company LLC lifted their price objective on shares of SI-BONE from $20.00 to $24.00 and gave the stock a “buy” rating in a research note on Tuesday, February 25th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and set a $25.00 price target on shares of SI-BONE in a report on Tuesday, February 25th. Five equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, SI-BONE currently has a consensus rating of “Buy” and an average price target of $24.40.

Insider Activity at SI-BONE

In related news, insider Anthony J. Recupero sold 3,670 shares of the stock in a transaction that occurred on Thursday, January 2nd. The shares were sold at an average price of $13.90, for a total value of $51,013.00. Following the completion of the transaction, the insider now directly owns 222,814 shares of the company’s stock, valued at $3,097,114.60. This trade represents a 1.62 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CFO Anshul Maheshwari sold 5,304 shares of the business’s stock in a transaction that occurred on Thursday, January 2nd. The stock was sold at an average price of $13.91, for a total transaction of $73,778.64. Following the sale, the chief financial officer now directly owns 189,319 shares in the company, valued at approximately $2,633,427.29. This represents a 2.73 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 9,311 shares of company stock valued at $130,356 over the last quarter. 3.90% of the stock is owned by corporate insiders.

SI-BONE Company Profile

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.